A Phase 1 Study to Assess the Safety and Immunogenicity of JCXH-221, an MRNA-based Broadly Protective COVID-19 Vaccine

NCT05743335 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

73

Enrollment

INDUSTRY

Sponsor class

Conditions

COVID-19
Infectious Disease

Interventions

BIOLOGICAL: JCXH-221
OTHER: Placebo

Sponsor

Immorna Biotherapeutics, Inc.

Collaborators

[object Object]